**Cell Cycle, Cell Death, and Senescence**

**Metformin Induces Both Caspase-Dependent and Poly(ADP-ribose) Polymerase-Dependent Cell Death in Breast Cancer Cells**

Yongxian Zhuang¹ and W. Keith Miskimins¹,²

**Abstract**

There is substantial evidence that metformin, a drug used to treat type 2 diabetics, is potentially useful as a therapeutic agent for cancer. However, a better understanding of the molecular mechanisms through which metformin promotes cell-cycle arrest and cell death of cancer cells is necessary. It will also be important to understand how the response of tumor cells differs from normal cells and why some tumor cells are resistant to the effects of metformin. We have found that exposure to metformin induces cell death in all but one line, MDA-MB-231, in a panel of breast cancer cell lines. MCF10A nontransformed breast epithelial cells were resistant to the cytotoxic effects of metformin, even after extended exposure to the drug. In sensitive lines, cell death was mediated by both apoptosis and a caspase-independent mechanism. The caspase-independent pathway involves activation of poly(ADP-ribose) polymerase (PARP) and correlates with enhanced synthesis of PARP and nuclear translocation of apoptosis-inducing factor (AIF), which plays an important role in mediating cell death. Metformin-induced, PARP-dependent cell death is associated with a striking enlargement of mitochondria. Mitochondrial enlargement was observed in all sensitive breast cancer cell lines but not in nontransformed cells or resistant MDA-MB-231. Mitochondrial enlargement was prevented by inhibiting PARP activity or expression. A caspase inhibitor blocked metformin-induced apoptosis but did not affect PARP-dependent cell death or mitochondrial enlargement. Thus, metformin has cytotoxic effects on breast cancer cells through 2 independent pathways. These findings will be pertinent to efforts directed at using metformin or related compounds for cancer therapy.

**Introduction**

Metformin is a drug that is commonly prescribed to treat type 2 diabetics. Recently, metformin has received attention as a potentially useful therapeutic agent for treating cancer. Population studies indicate that type 2 diabetics taking metformin have a significantly reduced risk of cancer and lower cancer-related mortality than diabetics not taking metformin (1–3). For diabetic patients with breast cancer, it was shown that patients on metformin had a significantly better response to neoadjuvant chemotherapy than patients not taking metformin (4). Preclinical animal model systems have shown reduced tumor growth with metformin for colon (5, 6), breast (7–9), pancreatic (10), and lung (11) cancers. One study using a rat model of chemically induced mammary carcinogenesis found no significant effects of metformin on tumor growth (12). Another study using xenografts of the human MDA-MB-435 cell line, now thought to be derived from melanoma (13), observed increased tumor growth with metformin treatment.

The mechanisms by which metformin produces its inhibitory effects on cancer development and tumor growth are not completely understood. These could be through indirect effects on systemic levels of insulin or glucose (14, 15), or through direct effects on tumor cell growth and survival. Direct effects of metformin on cancer cells include inhibition of cell proliferation (6, 9, 10, 16–22) and induction of cell death (5, 8, 9, 18, 19, 23). Inhibition of cancer cell proliferation in response to metformin appears to involve activation of AMP-activated protein kinase (AMPK; refs. 6, 9, 10, 17–19, 21, 22), inhibition of mTOR activity and protein translation (17), and downregulation of cyclin D1 leading to cell-cycle arrest in G1 (6, 9, 16, 22). In those studies where metformin has been shown to promote cell death, the mechanism appears to involve activation of apoptotic pathways (5, 9, 19, 24). In a colon cancer model system, metformin-stimulated apoptosis was specifically associated with the loss of p53-dependent enhancement of autophagy and glycolysis and was stimulated by nutrient...
deprivation (5). In other culture systems, metformin displayed enhanced cytotoxicity in combination with glucose deprivation (23, 25), cisplatin (18), doxorubicin (8, 26), or buthionine sulfoximine (26).

Based on recent epidemiological, clinical, and preclinical data there is growing interest in the potential use of metformin for treating cancer (27). In this regard, a better understanding of the molecular mechanisms and signaling pathways through which metformin promotes cell-cycle arrest and cell death of cancer cells is needed. It will be important to determine how the response of tumor cells differs from normal cells and why some tumor cells are resistant to the effects of metformin. In this study, we have examined metformin-induced cell death in a panel of breast cancer cell lines. All but one breast cancer cell line underwent cell death in response to metformin. Nontransformed breast epithelial cells were also resistant to the cytotoxic effects of metformin. In sensitive cell lines, cell death was mediated by both caspase-dependent and caspase-independent mechanisms. The caspase-independent pathway involved activation of poly(ADP-ribose) polymerase (PARP), was associated with mitochondrial enlargement, and was reduced by depletion of AIF.

Materials and Methods

Chemicals and cell culture
Metformin (1,1-dimethylbiguanide) was purchased from Sigma Chemical, PARP inhibitor II (INH2BP, 5-iodo-6-amino-1,2-benzopyrone) was purchased from Calbiochem, and caspase inhibitor (Q-Val-Asp-OPh) was purchased from MP Biomedicals. Caspase inhibitor sample pack (FMKSP01) was purchased from R&D systems. The cell lines MCF7, T47D, MDA-MB-453, BT474, MDA-MB-231, and MCF10A cells were purchased from American Type Culture Collection (ATCC). ATCC cell lines are authenticated by STR analysis. On receiving the cell lines, MCF7 and T47D cells were selected using 400 μg/mL G418 disulfate (Sigma). The cells were transferred from the cuvette into 35 mm dishes and cultured in DMEM containing 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories). For detection of endogenous proteins by immunofluorescence, cells were permeabilized in 0.25% Triton X-100 for 5 minutes and then washed in PBS 3 times. This was followed by blocking in 10% bovine serum albumin (BSA) in PBS for 30 minutes and then incubation in primary antibody for 2 hours at 37°C. Primary antibody (1:100) was prepared in 3% BSA in PBS. Slides were washed 3 times in PBS and incubated with Alexa Fluor 594–labeled secondary antibody (1:500, Molecular Probes) for 45 minutes. Finally, slides were washed in PBS 3 times and mounted using Vectashield medium containing DAPI. Slides were observed using an Olympus FV1000 confocal microscope. The following primary antibodies were used: AIF antibody (#4642, Cell Signaling) and PAR antibody (#550781, BD Pharmingen). Plasmids encoding mitochondrial targeted fluorescent proteins, pAcGFP1-Mito and pDsRed2-Mito, were purchased from Clontech.

Annexin V/propidium iodide staining
Cells were plated in 35 mm dishes and treated as indicated for 3 days. Cells were washed once in PBS and stained using the ApoAlert Annexin V–FITC Apoptosis Kit (Clontech Laboratories) as follows. Cells were washed with binding buffer and then 200 μL of binding buffer containing 5 μL of propidium iodide (PI) and 10 μL Annexin V–FITC (fluorescein isothiocyanate) was added. The cells were incubated for 10 minutes in the dark. The cells were observed by fluorescence microscopy using a dual filter set for FITC and rhodamine.

Electroporation
Cells were plated into 150 mm dishes and cultured in DMEM with 10% FBS for 2 days. Cells (2 × 10⁶) were trypsinized and pelleted at 90 × g for 10 minutes. The supernatant was completely discarded and the cells were resuspended at room temperature in Cell Line Nucleofector Solution V kit (Amaxa) to a final concentration of 2 × 10⁶ cells per 100 μL. The cell suspension was mixed with 2 μg DNA for each sample. The sample was transferred into an Amaxa cuvette and cells were electroporated using a Nucleofector II electroporation apparatus with program E-014. The cells were transferred from the cuvette into 35 mm dishes containing warm medium. Medium was changed after overnight incubation. Stably transfected cells were selected using 400 μg/mL G418 disulfate (Sigma).

Inhibition of AIF expression using siRNAs
ON-TARGET Plus Smart pool siRNA targeting AIF and nontargeting siRNA were purchased from Thermo Scientific. MCF7 cells that were ~30% confluent were transfected with the siRNAs using Lipofectamine 2000 (Invitrogen). One day after transfection the cells were treated with either DMSO or caspase inhibitor (10 μM/L) with or without metformin (8 mmol/L) for 3 days. Cells were trypsinized and trypan blue exclusion assays were used to count dead and live cells.
Western blotting

Cells in 35 mm dishes were rinsed with PBS and lysed by addition of 1× SDS sample buffer [2.5 mmol/L Tris–HCl (pH 6.8), 2.5% SDS, 100 mmol/L dithiothreitol, 10% glycerol, 0.025% pyronine Y]. Equal amounts of protein were separated on a 10% or 15% SDS-polyacrylamide gel. Proteins were transferred to Immobilon P membranes (Millipore) using a Bio-Rad Trans-blot apparatus with a transfer buffer of 48 mmol/L Tris–HCl and 39 mmol/L glycine. The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline [10 mmol/L Tris–HCl (pH 7.5), 150 mmol/L NaCl] containing 0.1% Tween-20 (TBS-T) for 15 to 60 minutes at room temperature. The membrane was then incubated with the appropriate antibody in TBS-T containing 5% nonfat dry milk for 1 hour at room temperature or overnight at 4°C. After extensive washing in TBS-T, the membrane was incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody. After extensive washing in TBS-T, proteins were detected using the Super Signal West Pico chemiluminescent substrate (Pierce Biochemical). Anti-β-actin monoclonal antibody (1:10,000) was purchased from Sigma Chemical. Antibodies to PARP (#9542, used at 1:1,000), cleaved caspase 7 (#9491, used at 1:1,000), and AIF (#4642, used at 1:1,000) were purchased from Cell Signaling. Secondary HRP-linked anti-mouse and anti-rabbit IgG antibodies (used at 1:5,000) were purchased from Pierce Biochemical.

Transmission electron microscopy

Cells were treated with or without metformin for 2.5 days, trypsinized, and pelleted by centrifuging for 5 minutes at 1000 rpm in a MicroCL17R centrifuge. They were then washed in PBS and pelleted at 1000 rpm for 5 minutes. Cell pellets were fixed using 4% formaldehyde–1% glutaraldehyde. Cells remained in the fixative for a minimum of 1 hour. The pellet was rinsed 3 times with PBS for 5 minutes and the pellet was postfixed with buffered 1% osmium tetroxide for not less than 1 hour and no more than 2 hours. The pellet was rinsed with distilled water 3 times for 5 minutes each. Then it was dehydrated by rinsing sequentially with 50% ethanol, 70% ethanol, and 95% ethanol, twice each, for 5 minutes. Then the pellet was immersed in 100% acetone for 10 minutes. This was repeated 3 times. Infiltration was continued as follows. The dehydrated pellet was immersed into 1 part catalyzed resin to 2 parts acetone for a minimum of 30 minutes, 2 parts catalyzed resin to 1 part acetone for a minimum of 60 minutes, and 100% catalyzed resin for a minimum of 1 hour. The infiltrated pellet was embedded into catalyzed resin, and blocks were cured for 8 hours in a 60°C oven. Thick sections were cut from the capsule and then 1-μm sections were cut. The last good section cut from the block was floated on distilled water. Then the sections were stained with toluidine blue. Thin sections were then double stained using uranyl acetate (saturated uranyl acetate in 50% ethanol) and 2% lead citrate. Specimens were observed using a JEOL 1210 transmission electron microscope at 8,000× or 15,000× magnification.

Flow cytometry

MCF7 cells were treated with or without metformin for 3 days and then processed using the ApoAlert Annexin V–FITC Apoptosis Kit (Clontech Laboratories). Cells were trypsinized and then pelleted by centrifugation. The cell pellet was washed in 1× PBS and then in 1× binding buffer. The cells were pelleted again and resuspended in 200 μL 1× binding buffer. Annexin V (5 μL) and PI (5 μL) were added and the cell suspension was incubated for 10 minutes in the dark. All flow cytometry measurements were carried out using an Accuri C6 flow cytometer.

Results

Metformin induces cell death in most breast cancer cells but not nontransformed mammary epithelial MCF10A cells

Previously we treated MCF7 cells with metformin for 1 to 2 days, and found that MCF7 cell proliferation was inhibited (22). With an extended time of treatment many cells detach from the dish and appear to be dead. To examine this further, live cell numbers were measured using a trypan blue exclusion assay (Fig. 1A). Over the first 2 days of metformin treatment, MCF7 cells were inhibited from proliferating as compared with controls, but by the third day the cell

![Image](https://example.com/image.png)

**Figure 1.** Metformin induces cell death in breast cancer cells. A, MCF7 cells were treated with metformin (8 mmol/L) for the indicated time. Live cells were counted using a trypan blue exclusion assay to obtain a growth curve. B, MCF7 and T47D were treated without (−) or with 8 mmol/L metformin (+) for 3 days and MDA-MB-453, BT474, MDA-MB-231 and MCF10A were treated for 4 days. The percent of dead cells in the population was determined by trypan blue exclusion.
number started to decrease due to increased cell death. To determine if the cytotoxic effects of metformin are limited to MCF7 cells, we treated a panel of breast cancer cell lines with the drug. Live and dead cells were counted and the percentage of dead cells was determined (Fig. 1B). T47D, MDA-MB-453, BT474, in addition to MCF7, underwent cell death in response to metformin. The breast cancer cell line MDA-MB-231 was resistant to the drug and showed almost no increase in cell death. The nontransformed human mammary epithelial cell line, MCF10A, was also resistant to the cytotoxic effects of metformin. MCF7 and T47D were the most sensitive of the breast cancer cell lines as indicated by the greater number of dead cells and shorter time to cell death. Even with extended treatment times, no significant cell death was observed in metformin-treated MDA-MB-231 or MCF10A cells (data not shown). MCF10A cells remained viable in the presence of metformin for up to 2 weeks, although proliferation was reduced relative to untreated cultures (data not shown). These data suggest that metformin promotes cell death in most breast cancer cells but not in normal mammary epithelial cells.

**Cell death induced by metformin has features of apoptosis**

To define the type of cell death caused by metformin in MCF7 cells, Western blotting was carried out to detect cleaved caspase 7, cleaved PARP1 and PARP1. MCF7 cells do not express caspase 3, but the executioner caspase 7 has previously been shown to be activated downstream of mitochondria-mediated apoptosis in this cell line (28). PARP1 is a substrate for both caspases 3 and 7 and cleaved PARP1 is a hallmark of caspase-dependent apoptosis. Cleaved caspase 7, the active form of the enzyme, was detected by the third day after metformin treatment and paralleled an increase in PARP1 cleavage (Fig. 2A). This suggests that an apoptotic cell death pathway is stimulated by metformin. To further explore this, MCF7 cells were treated with metformin and Annexin V–FITC/PI staining

![Figure 2.](image-url)
was carried out (Fig. 2B). Annexin V–FITC staining indicates that cells are dying through apoptosis whereas PI staining indicates that the cells have damaged plasma membranes and are dead. After metformin treatment for 3 days, there is an increase in the number of cells that are Annexin V positive and PI negative, as well as an increase in the number of cells that are positive for both. Quantification by flow cytometry indicates that 23.6% of the cells are Annexin V positive in metformin-treated cultures as compared with 2.27% in control cultures (Fig. 2B, right). To confirm caspase-dependent apoptotic cell death, MCF7 cells were cotreated with an irreversible broad spectrum caspase inhibitor (Q-Val-Asp-OPh, 10 μmol/L) and metformin for approximately 2.5 days and cells were harvested for Western blotting. The pan-caspase inhibitor completely blocked activation of caspase 7 and cleavage of PARP in the metformin-treated cells (Fig. 2C). Interestingly, we routinely observe a decrease in both full-length PARP and caspase 7 when cells are incubated with metformin and caspase inhibitors. This decrease does not correspond to an increase in cleaved forms of the protein but may be related to the activation of AMPK and subsequent inhibition of mTOR, which leads to decreased protein synthesis. Metformin-induced activation of caspase 7 was also blocked by inhibitors that are specific for caspases 3/7 and 9, but not by an inhibitor of caspase 8 (Supplementary Fig. S1A). The effect of the pan-caspase inhibitor on metformin-induced cell death was also monitored (Fig. 2D). MCF7 cells were cotreated with metformin and the pan-caspase inhibitor for 2.5 days and then the number of live and dead cells in the cultures was determined (Fig. 2D, left). Cell death in metformin-treated cells was almost completely blocked by the presence of the caspase inhibitor at this time point, indicating that cells are dying through caspase-dependent apoptosis.

Even though inhibition of caspases was effective at blocking cell death at 2.5 days, extended incubation with metformin led to cell death regardless of the presence of Q-Val-Asp-OPh (Fig. 2D, right). In fact, there was more cell death in the presence of the pan-caspase inhibitor at this time point. These results suggest that a second, caspase-independent, mechanism of cell death is promoted by metformin in this breast cancer cell line. Therefore, further experiments were carried out to explore other potential mechanisms of cell death in metformin-treated breast cancer cells.

Metformin causes significant morphological changes in mitochondria that correlate with sensitivity to the drug

Treatment of MCF7 cells with metformin leads to a striking accumulation of large, clear vesicles that are noticeably visible by phase contrast microscopy (Fig. 3A). These vesicles are observed in all of the metformin-sensitive breast cancer cell lines that have been examined (T47D, MDA-MB-453, BT474) but not in MDA-MB-231 or MCF-10A cells, which are resistant to the cytotoxic effects of the drug (Fig. 3A). The vesicles accumulate throughout the cytosol but appear to be most dense around the nucleus. To determine the origin of the vacuoles, transmission electron microscopy (TEM) was used. MCF7 cells were treated with metformin for 3 days and then harvested for TEM analysis (Fig. 3B). Compared with control cells, numerous enlarged organelles are observed in metformin-treated cells. These organelles retain features of mitochondria, including clearly defined cristae (Fig. 3B). These results suggest that the vesicles observed by phase contrast microscopy are actually enlarged mitochondria. To confirm this, MCF7 cells were transfected with a construct encoding DsRed-Mito. This construct encodes a red fluorescent protein that is specifically targeted to mitochondria. After transfection, cells were treated with metformin for 2.5 days and then observed by confocal microscopy. Metformin treatment causes significant morphological changes in DsRed-stained mitochondria (Fig. 3C). The mitochondria become enlarged and the DsRed-Mito signal becomes diffuse. Together these results show that metformin promotes morphological changes in mitochondria, including a dramatic enlargement and loss of internal structure. Because these mitochondrial changes are associated with sensitivity to metformin-induced cytotoxicity, we further explored their relationship to cell death mechanisms.

Metformin induces PARP-dependent cell death that correlates with mitochondrial enlargement

A second form of cell death that is associated with mitochondrial changes, but is caspase independent, is PARP-dependent cell death. This form of cell death is distinguishable from apoptosis, autophagic cell death, and necrosis (29). It is initiated by overactivation of PARP and synthesis of its product PAR. PAR signals mitochondria to release AIF, which translocates to the nucleus to facilitate cell death. Previously, it was shown that AIF release mediates delayed onset cell death when the caspase-dependent pathway is blocked (30). We therefore examined the possibility that PARP-dependent cell death is initiated in metformin-treated breast cancer cells. MCF7 cells were treated with metformin for 4 days in the presence or absence of a chemical inhibitor of PARP and then the percentage of dead cells in the culture was determined (Fig. 4A, left). Inhibition of PARP led to a significant decrease in metformin-induced cell death. The effect of the PARP inhibitor is even greater when the cells are also treated with a pan-caspase inhibitor. This was further examined in a time course experiment in which the effects on metformin-induced cell death by the pan-caspase inhibitor, PARP inhibitor, or both was examined (Supplementary Fig. S1B). The PARP inhibitor, alone, does not significantly reduce cell death until 3.5 days; whereas the pan-caspase inhibitor is effective at 1.5 and 2.5 days but not at 3.5 days. These results support the conclusion that metformin induces both PARP-dependent and caspase-dependent apoptotic cell death and that the PARP-dependent mechanism is delayed relative to apoptosis.

To confirm results obtained using the chemical inhibitor of PARP, a cell line (MCF7-shPARP1) in which PARP1 expression is stably repressed via a shRNA (short hairpin RNA) was used (31). A cell line expressing an shRNA targeted to luciferase (MCF7-shLuc) was used as a control.
MCF7-shLuc responds to metformin in a manner very similar to the parental cell line. After 2 days, a significant number of dead cells were observed in the metformin-treated culture (Fig. 4B, left). Cell death corresponded to activation of caspase 7 and the appearance of cleaved PARP1, and it was substantially blocked by inclusion of the pan-caspase inhibitor (Fig. 4B and C). Two-day treatment of MCF7-shPARP1 also led to substantial cell death but this was reduced compared with control cells. Following 3 days of metformin treatment, inhibition of caspases no longer blocked cell death in the control MCF7-shLuc cells but almost completely blocked cell death in MCF7-shPARP1 (Fig. 4B, right). Metformin-induced activation of caspase 7 in MCF7-shPARP1 and this was also completely blocked by the pan-caspase inhibitor (Fig. 4C).

These results further support the conclusion that metformin induces caspase-dependent apoptotic cell death as well as a delayed form of cell death that is PARP dependent.

Because cell death in response to metformin correlates with mitochondrial enlargement, we wanted to determine if this is associated with apoptosis, PARP-dependent cell death, or both. MCF7 cells were treated with metformin in the presence or absence of caspase inhibitor, PARP inhibitor, or both and then examined by phase contrast microscopy (Fig. 5A). Inhibition of caspases had no effect on the formation of enlarged mitochondria that appear as phase transparent “vacuoles” in the cytoplasm. In contrast, inclusion of the PARP inhibitor almost completely blocked formation of the vacuoles. These results were confirmed using MCF7 cells stably expressing mitochondrial-targeted...
PARP1, cleaved caspase 7, full-length caspase 7, and extracts from cells treated as in B were analyzed by Western blotting for inhibitor as indicated for either 2 days (left) or 3 days (right). The percentage targeting PARP1 (shPARP) were treated with metformin and pan-caspase MCF7 cells stably expressing either a control shRNA (shLuc) or an shRNA (PARP Inh). Right, MCF7 cells were treated for 4 days with (þ metformin in the presence of either vehicle (DMSO) or PARP inhibitor. Differences between the indicated groups (*, **, P < 0.02; ***, P < 0.001). B. MCF7 cells stably expressing either a control shRNA (shLuc) or an shRNA targeting PARP1 (shPARP) were treated with metformin and pan-caspase inhibitor as indicated for either 2 days (left) or 3 days (right). The percentage of dead cells in each dish was obtained via trypan blue exclusion assay. A t test was used to determine statistical differences between the indicated groups (*, P < 0.02; ***, P < 0.001). B. MCF7 cells stably expressing either a control shRNA (shLuc) or an shRNA targeting PARP1 (shPARP) were treated with metformin and pan-caspase inhibitor as indicated for either 2 days (left) or 3 days (right). The percentage of dead cells in each dish was obtained via trypan blue exclusion assay. A, extracts from cells treated as in B were analyzed by Western blotting for PARP1, cleaved caspase 7, full-length caspase 7, and β-actin.

Figure 4. Metformin induces PARP-dependent cell death in MCF7 cells. A (left), MCF7 cells were treated for 4 days with (+) or without (–) metformin in the presence of either vehicle (DMSO) or PARP inhibitor (PARP Inh). Right, MCF7 cells were treated for 4 days with (+) or without (–) metformin in the presence of a pan-caspase inhibitor (Q-Val-Asp-OPh, 10 μmol/L) and either vehicle (DMSO) or PARP inhibitor (PARP Inh). The percentage of dead cells in each dish was obtained via trypan blue exclusion assay. A t test was used to determine statistical differences between the indicated groups (*, P < 0.02; ***, P < 0.001). B. MCF7 cells stably expressing either a control shRNA (shLuc) or an shRNA targeting PARP1 (shPARP) were treated with metformin and pan-caspase inhibitor as indicated for either 2 days (left) or 3 days (right). The percentage of dead cells in each dish was obtained via trypan blue exclusion assay. C, extracts from cells treated as in B were analyzed by Western blotting for PARP1, cleaved caspase 7, full-length caspase 7, and β-actin.

pAcGFP1 (Fig. 5B). In addition, MCF7-shLuc and MCF7-shPARP1 cells were treated with metformin in the presence and absence of caspase inhibitor and then observed by phase contrast microscopy. No enlarged mitochondrial were observed in MCF7-shPARP1 cells under any conditions (Fig. 5C). MCF7-shLuc cells behaved exactly like the parental cell line and enlarged mitochondrial appeared after treatment with metformin even in the presence of caspase inhibitor. It can be concluded that mitochondrial enlargement is specifically associated with PARP1 activation and PARP-dependent cell death.

Metformin treatment of sensitive breast cancer cells leads to enhanced PAR synthesis and release of AIF from mitochondria

PARP1 is a nuclear enzyme that catalyzes the synthesis of PAR. PAR has been shown to be an important signaling component of PARP-dependent cell death. Because metformin stimulates a delayed cell death response that is blocked by chemical inhibitors of PARP, or by siRNA-mediated repression of the enzyme, we examined various aspects of the PARP-dependent cell death pathway. Metformin-sensitive MCF7 cells or metformin-resistant MDA-MB-231 cells were treated with the drug for 2.5 days. PAR, the product of PARP, was then detected using immunofluorescence (Fig. 6A and B). In MCF7, PAR was not detectable in untreated control cells but was induced by metformin (Fig. 6A, left). Induction of PAR synthesis by metformin was almost completely blocked by cotreatment with a PARP inhibitor (Fig. 6B). For MDA-MB-231, there was no difference in PAR levels between control and metformin-treated cells (Fig. 6A, right). Thus, PARP activation in response to metformin is limited to cells that undergo cell death when treated with the drug.

AIF, another key mediator of PARP-dependent cell death, is normally localized to the intermembrane space of mitochondria. PAR promotes translocation of AIF from mitochondria to the nucleus, causing DNA condensation and fragmentation, and subsequent cell death in a caspase-independent manner (32). To examine effects on AIF localization, MCF7 cells were treated with metformin, with or without PARP inhibitor, and then AIF was detected using immunofluorescence (Fig. 7A). In control cells, as expected, the pattern of AIF staining is consistent with localization to mitochondria. Metformin caused mitochondria to enlarge and AIF was excluded from these mitochondria. Release of AIF and mitochondrial enlargement in metformin-treated cells was inhibited by cotreatment with PARP inhibitor (Fig. 7A). Nuclear uptake of AIF is a key event in PARP-dependent cell death. To examine this, MCF7 cells were treated with and without metformin for 3 days. Nuclear extracts were prepared and AIF was detected by Western blotting (Fig. 7B). In metformin-treated cells, AIF was clearly present in the nuclear fraction but almost undetectable in control cells. To determine if AIF plays a role in metformin-induced cell death, MCF7 cells were transfected with a control siRNA or an siRNA targeted to AIF. In cells transfected with the AIF-targeted siRNA, expression of the protein was reduced by ~65% (Fig. 7C) and metformin-induced cell death was significantly reduced (Fig. 7D). The inhibition of cell death in cells with reduced AIF expression was even greater when cells were also treated with pan-caspase inhibitor. Thus, AIF plays an important role in the metformin-induced caspase-independent cell death mechanism that functions downstream of PARP activation.

Discussion

Metformin has previously been shown to inhibit proliferation of various types of cancer cells (6, 9, 10, 16–22). In addition, metformin has been shown to promote cell death of some cancer cells through activation of apoptotic pathways (5, 9, 19, 24). The data presented here confirm
metformin-induced killing of breast cancer cells through apoptosis. Buzzai and colleagues (5) showed that metformin-stimulated apoptosis of colon cancer cells was associated with loss of p53-dependent enhancement of autophagy and glycolysis and that cell killing was stimulated by nutrient deprivation. In contrast, Ben Sahra and colleagues (33) showed that, in the presence of 2-deoxyglucose, metformin promotes apoptosis of prostate cancer cells in a p53-dependent manner. For breast cancer cells, p53 status does not seem to govern sensitivity to metformin. The cell lines T47D, MDA-MB-453, BT474, and MCF7 are all sensitive to the cytotoxic effects of metformin. MCF7 expresses wild-type p53 whereas all the other lines express mutated p53. MDA-MB-231, which continues to grow at concentrations that kill the other breast cancer cell lines, also expresses mutated p53.

A novel finding of the work presented here is that metformin induces a second form of cell death in breast cancer cells. This mode of cell death is dependent on PARP but independent of caspase activity. It is blocked by chemical inhibition of PARP enzymatic activity and does not occur at significant levels in cells where PARP1 expression is repressed by shRNAs. PARP-mediated cell death has been observed under a number of different circumstances, including treatment with DNA alkylating agents, following oxidative DNA damage, treatment with neurotoxic...
compounds, and ischemia (30, 32, 34–47). PARP-dependent cell death appears to be a unique form of programmed cell death that is distinct from apoptosis, autophagic cell death, or necrosis (29). It was recently named parthanatos to distinguish it from the other forms of cell death (48). Key events in this cell death pathway include activation of PARP, extensive synthesis of PAR, signaling of PAR to the mitochondria, release of AIF from mitochondria, and nuclear uptake of AIF (29). Here we show that metformin treatment of MCF7 cells enhances both PAR synthesis and AIF uptake into the nuclear compartment. Reduction of AIF expression also reduced metformin-induced cell death. Elevated PAR synthesis is not observed in MDA-MB-231 cells that are resistant to the cytotoxic effects of metformin. Hyperactivation of PARP also may cause cell death by depleting cellular NAD$^+$ levels. Because NAD$^+$ is required for both glycolysis and oxidative metabolism in mitochondria, depletion could lead to cellular energy collapse and subsequent cell death. Such a mechanism has previously been described for cell death in response to alkylating agents (32, 47) and has been referred to as “metabolic catastrophe” (49). It may be that cancer cells are more sensitive than normal cells to energy collapse because of high energy requirements for unrestricted proliferation. Depletion of cellular levels of NAD$^+$ may also affect cell survival through mechanisms other than energy collapse. Alano and colleagues (50) showed that addition of NAD$^+$ to the culture medium was able to block PARP-dependent translocation of AIF to the nucleus of astrocytes treated with DNA damaging agents. Overexpression of nicotinamide phosphoribosyltransferase (NAMPT), the rate limiting enzyme in the synthesis of NAD$^+$ from nicotinamide, protects cells from cell death in response to genotoxic compounds (51). This protective effect requires mitochondrial sirtuins, SIRT3 and SIRT4. It is possible that sensitivity to the cytotoxic effects of metformin is related to the cellular levels of NAMPT or sirtuins and it will be of interest to compare the levels and activity of these enzymes in sensitive and resistant cell lines.

PARP-dependent cell death of metformin-treated cells appears to be delayed relative to apoptotic cell death and is associated with changes in mitochondrial morphology. In all metformin sensitive breast cancer cell lines examined, mitochondria become enlarged and this is blocked by PARP inhibitors but not by caspase inhibition. Metformin-induced mitochondrial enlargement was also inhibited by genetically repressing PARP1 expression in MCF7 cells. Inhibition of PARP blocks mitochondrial enlargement but does not prevent metformin-induced apoptotic cell death. Thus, mitochondrial enlargement is specifically associated with the PARP-dependent cell death pathway in response to metformin. PARP-dependent cell death has previously been associated with the mitochondrial permeability transition (MPT; ref. 50). MPT causes mitochondria to become permeable to small molecules and

![Figure 6](image-url)
this leads to osmotic swelling of the organelles. MPT is inhibited by cyclosporin A or bongkrekic (52, 53) but we have been unable to prevent metformin-induced mitochondrial enlargement with either of these reagents (data not shown). Previously dos Santos and colleagues (54) observed cyclosporine A–insensitive MPT induction that was associated with complex I inhibition. At present it is not clear what process leads to mitochondrial enlargement following metformin treatment or how this relates to PARP activation.

Metformin is known to be taken up and concentrated in mitochondria where it inhibits complex I of the electron transport chain (55). This leads to loss of mitochondrial membrane potential and inhibition of ATP production. Inhibition of complex I also promotes superoxide production within the mitochondrial matrix which could cause damage to mitochondrial proteins, lipids, and nucleic acids. These effects may lead to apoptotic cell death. However, it is difficult to connect them directly to PARP-dependent cell death. PARP1 is primarily a nuclear protein that is activated by DNA damage. Therefore, one possibility is that metformin-induced superoxide production within the mitochondrial matrix leads to accumulation of reactive oxygen species throughout the cell, causing nuclear DNA damage, PARP activation, PAR synthesis, and signaling back to mitochondria to promote AIF release and cell death. Another possibility is that mitochondrial-localized PARP1 is a key enzyme in metformin-induced cell death. There is substantial evidence that PAR synthesis takes place in mitochondria and that a portion of PARP1 localizes to this organelle (56–62). Du and colleagues (57) showed that cell death induced by oxidative stress involves mitochondrial PARP1. Inhibition of mitochondrial PARP1 prevented NAD$^+$ depletion within mitochondria, loss of mitochondrial membrane potential,
release and nuclear uptake of AIF, and reduced cell death. It is therefore possible that PARP-dependent cell death induced by metformin is the result of oxidative damage to mitochondrial DNA, activation of mitochondrial PARP1, and depletion of mitochondrial NAD$^+$. Several interesting questions remain to be answered. For example, why are nontransformed cells and some breast cancer cell lines less sensitive to the cytotoxic effects of metformin? One possibility is that resistant cells are inefficient at taking up and accumulating metformin. This seems unlikely for the resistant breast cancer cell line MDA-MB-231. We previously showed that this line responds to metformin in terms of activation of AMPK and downregulation of cyclin D1 (22). When p27Kip1 is overexpressed, this line undergoes cell-cycle arrest in response to metformin but is still resistant to the cytotoxic effects of the drug (22). Likewise, metformin slows proliferation of nontransformed MCF10A cells but does not cause cell death. This suggests that resistance to metformin-induced cell death is not due to a lack of uptake and is also independent of effects on cell-cycle progression. Because complex I of the mitochondrial electron transport chain is a primary target of metformin, and all the sensitive breast cancer cells accumulate enlarged mitochondria, it is likely that differences between sensitive and resistant cell lines reside within this organelle. Several possibilities exist. Resistant cells may have higher levels or activity of the mitochondrial superoxide dismutase, MnSOD, allowing them to more effectively eliminate complex I–derived superoxide and prevent damage to mitochondria. Many breast cancers express lower levels of MnSOD than normal surrounding tissue (63). The cell lines MCF10A and MDA-MB-231, both resistant to metformin cytotoxicity, express higher levels of MnSOD than MCF7 and T47D which are both sensitive to metformin (64). Resistant cells may have more efficient mechanisms for preventing or repairing oxidative damage caused by superoxide production within mitochondria, thus limiting initiation of apoptotic and PARP-dependent cell death pathways. Recent findings suggest that mitochondrial integrity is maintained by removal of damaged mitochondria through autophagy (65–69). This process, called mitophagy, is thought to be coupled to mitochondrial fission and to involve specific recognition of damaged mitochondria by the autophagic machinery. Inefficient removal of damaged mitochondria through mitophagy could contribute to metformin-induced cell death. Another possibility is that sensitive cells have reduced capacity for maintaining cellular or mitochondrial NAD$^+$ levels, perhaps related to changes in NAMPT expression. These and other possibilities will need to be examined experimentally.

Diabetics taking metformin have a lower risk of cancer (1–3) and metformin has been found to enhance neoadjuvant therapy for diabetic breast cancer patients (4). Metformin also inhibits growth of breast tumors in preclinical mouse models (7–9). Thus, an interesting question is whether apoptosis, PARP-dependent cell death, or both, play a role in the inhibitory effects of the drug on cancer development and tumor growth. This can be addressed, in mouse xenograft models, using shRNA technology to knockdown key factors in the cell death pathways combined with specific inhibitors of PARP or caspases. Such studies will provide essential information concerning the potential use of metformin and related drugs in the treatment of cancer and how they may be used to complement other therapeutic approaches.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Dr. W. Lee Kraus for providing the MCF7 shLuciferase and shPARP1 stable cell lines.

Grant Support

US Public Health Service, National Cancer Institute, B01CA084325 (W.K. Miskimins) and Susan G. Komen for the Cure grant KG100497 (W.K. Miskimins).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 29, 2010; revised February 10, 2011; accepted February 28, 2011; published OnlineFirst March 21, 2011.

References


Molecular Cancer Research

Metformin Induces Both Caspase-Dependent and Poly(ADP-ribose) Polymerase-Dependent Cell Death in Breast Cancer Cells

Yongxian Zhuang and W. Keith Miskimins


Updated version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-10-0343

Supplementary Material
Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2011/05/17/1541-7786.MCR-10-0343.DC1

Cited articles
This article cites 68 articles, 36 of which you can access for free at:
http://mcr.aacrjournals.org/content/9/5/603.full.html#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
/content/9/5/603.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.